Rosen Law Encourages SAGE Investors to Act Before Securities Class Action Deadline

NEW YORK, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Rosen Law Firm, renowned for advocating on behalf of shareholders worldwide, has issued a notice to investors of Sage Therapeutics, Inc. SAGE. The announcement marks the commencement of a class action lawsuit focused on individuals who acquired securities in the company from April 12, 2021, to July 23, 2024, both dates inclusive. This lawsuit signifies an essential step in protecting the rights of the investor community against possible securities law violations.

Understanding the Allegations

The lawsuit alleges that Sage Therapeutics may have issued materially misleading business information to the investing public. Consequently, investors suffered damages upon the revelation of adverse information. As a biopharmaceutical company specializing in the development of treatments for central nervous system disorders, the integrity of information from Sage Therapeutics is vital for investors. Headquartered in Cambridge, Massachusetts, Sage Therapeutics has established itself as an innovative entity within the biopharma sector.

Legal Recourse for Investors

Rosen Law Firm is calling upon SAGE investors who have incurred losses to secure legal counsel prior to an impending deadline. The firm urges affected shareholders to be proactive in securing their legal rights. Investors who join the class action may recover their financial losses and also hold significant roles in holding the company accountable for its actions.

Rosen, Sage, Legal